You are here: Industry Insights > TGA

News List

Australian TGA grants approval to two oral medicines for Covid-19 Pharmaceutical-Technology
January 21, 2022
The Australian Therapeutic Goods Administration (TGA) has provisionally approved the use of two oral Covid-19 treatments, Merck Sharp & Dohme’s Lagevrio (molnupiravir) and Pfizer’s Paxlovid (nirmatrelvir and ritonavir).
Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine prnasia
January 20, 2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Australia's Therapeutic Goods Administration...
TGA provisionally approves GlaxoSmithKline's COVID-19 treatment: sotrovimab (XEVUDY) firstwordpharma
August 23, 2021
On 20 August 2021, the Therapeutic Goods Administration (TGA), part of the Department of Health, granted provisional approval to GlaxoSmithKline (GSK) Australia Pty Ltd for its COVID-19 treatment - sotrovimab (XEVUDY) - making it the second COVID-19.
Additional COVID-19 treatment for Australia firstwordpharma
August 09, 2021
The Australian Government has secured an initial shipment of over 7,700 doses of the novel monoclonal antibody treatment sotrovimab.
TGA approves Pfizer COVID-19 vaccine for 12 to 15-year-olds firstwordpharma
July 23, 2021
Australia’s COVID-19 vaccination rollout has taken another step forward with the Pfizer vaccine being approved for use in children aged 12 to 15 years.
Australian TGA approves Vertex’s Trikafta for cystic fibrosis treatment pharmaceutical-technology
March 26, 2021
The Australian Therapeutic Goods Administration (TGA) has approved the use of Vertex Pharmaceutical’s Trikafta (elexacaftor, tezacaftor, ivacaftor and ivacaftor) for people with cystic fibrosis (CF) aged 12 years and above.
WellmarkerBio receives approval for Phase I clinical trial from the Australian Therapeutic Goods Administration prnasia
March 04, 2021
Wellmarker Bio announced that on February 23, 2021 the company received approval from the Australian Therapeutic Goods Administration (TGA) for a Phase I clinical trial using WM-S1-030, a targeted anti-cancer drug for colorectal cancer and progressive ...
Australia approves Pfizer-BioNTech’s Covid-19 vaccine pharmaceutical-technology
January 26, 2021
Australia’s Therapeutic Goods Administration (TGA) has provisionally approved the Pfizer-BioNTech Covid-19 vaccine for use in people aged 16 years and above.
Australia’s TGA approves remdesivir as first Covid-19 treatment pharmaceutical-technology
July 14, 2020
The Therapeutic Goods Administration (TGA) of Australia has awarded provisional approval for the use of Gilead Sciences’ remdesivir (Veklury) to treat Covid-19 patients, marking the first authorisation of treatment for this disease in the country.
New Drug for Diabetes-Induced Vision Loss TGA-Approved for Australian Patients prnasia
August 06, 2019
Australian patients with diabetes-induced eye disease can now access a new treatment option that provides consistent and continuous treatment with long-lasting effect.

Previous page 1 2 Next page